Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00619476 · ClinicalTrials.gov registry record · Phase 2
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
A Phase 2 study, sponsored by XenoPort.
- Completed
- Registry status
- Phase 2
- Development phase
- 376
- Enrollment target
NCT00619476 is a Phase 2 study that has completed, run by XenoPort. The registered enrollment target is 376 participants.
The verdict
NCT00619476, a Phase 2 study, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 376 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).
Interventions
- DRUG Placebo
- DRUG GEn 1200mg/day
- DRUG GEn 3600mg/day
- DRUG GEn 2400mg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00619476
The ClinicalTrials.gov registry entry for NCT00619476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is XenoPort, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00619476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00619476 about?
NCT00619476 is a clinical study titled "A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)". The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).
What is the current status of trial NCT00619476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 376 participants. The study started on 2008-02. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00619476?
The interventions under investigation include: Placebo (DRUG), GEn 1200mg/day (DRUG), GEn 3600mg/day (DRUG), GEn 2400mg/day (DRUG).
Who is sponsoring clinical trial NCT00619476?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.